
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- VYLOY 成为欧盟首个也是目前唯一获批的靶向 CLDN18.2药物,38%的晚期胃癌患者CLDN18.2表达呈阳性1,2 - III期研究结果显示靶向...
Read more about 安斯泰来 VYLOY (佐妥昔单抗) 获欧盟批准与化疗联合用于治疗晚期胃或胃食管交界处腺癌
2023年9月17日是第五个世界患者安全日(World Patient Safety Day),本次世界患者安全日主题是“患者安全需要患者参与”。口号是“提高患者的发言权”。
-此次获批成为近40年来,首个在晚期尿路上皮癌中被证实疗效优于标准治疗含铂化疗的治疗方案 1...
Read more about 欧盟批准安斯泰来备思复(维恩妥尤单抗)联合可瑞达(帕博利珠单抗)用于一线治疗晚期尿路上皮癌
-这项批准基于全球EV-301研究和中国EV-203研究的结果,维恩妥尤单抗显著改善了既往接受过含铂化疗和PD-1/L1抑制剂治疗患者的总生存期(OS)和客观缓
Read more about 中国国家药品监督管理局批准备思复(注射用维恩妥尤单抗)用于治疗局部晚期或转移性尿路上皮癌
